Global competition for China’s biotechnology innovations is entering a more aggressive phase as venture capital firms increasingly shift their focus toward early stage scientific research rather than waiting for assets to reach commercialization. Investors, particularly from the United States, are embedding themselves directly
Hong Kong based CK Life Sciences is preparing to advance its cancer vaccine pipeline into mainland China using a faster clinical development pathway as the country expands support for early stage drug innovation. Backed by the business empire of Li Ka-shing, the company
Chinese biotechnology company Hangzhou Diagens Biotechnology is expanding the use of artificial intelligence driven chromosome testing to improve efficiency in in vitro fertilisation and strengthen its commercial growth strategy. The initiative comes as China faces declining birth rates and increasing demand for assisted
China’s pharmaceutical sector is rapidly moving into the global weight loss drug race after the expiration of Novo Nordisk’s semaglutide patent in the country, unlocking a major commercial opportunity for domestic developers. The shift comes as demand for obesity treatments surges worldwide and
US researchers and agritech companies are intensifying efforts to revive the struggling wheat sector by developing hybrid and genetically modified seeds designed to boost yields and improve resilience against climate stress. Scientists are experimenting with advanced genetic traits, including drought resistance, as the
Gilead Sciences has agreed to acquire US based biotech firm Ouro Medicines in a deal valued at up to 2.18 billion dollars, gaining access to a promising antibody based treatment originally licensed from China’s Keymed Biosciences. The transaction highlights the growing importance of
A prominent life scientist with deep ties to US research institutions has shifted his academic base to China, highlighting a growing trend of talent movement in global science. Shu Xiaokun, known for his work in advanced biological imaging and molecular tools, has returned
Major international pharmaceutical companies are accelerating their expansion in China, signaling a strategic shift toward localized production as global supply chains become more fragmented. AstraZeneca has announced plans to establish new drug manufacturing facilities in Guangzhou and Shanghai, alongside a dedicated innovation centre
Growing reliance on China’s pharmaceutical supply chain is raising concerns among US policymakers, who warn that dependence on foreign sources for critical drug ingredients could pose long term risks to healthcare security. Lawmakers are increasingly focused on how China has expanded its role
AstraZeneca is deepening its presence in China’s fast growing biotech sector with plans to build a new cell therapy facility in Shanghai, reinforcing its long term commitment to advanced medical innovation in the region. The investment forms part of a broader expansion strategy
